Addressing factors modulating COVID-19 is crucial since abundant clinical evidence shows
that outcomes are markedly heterogeneous between patients. This requires identifying the …

Individualization of drug therapy requires that the right drug be administered at the correct
dose to patients who are likely to achieve the highest benefit and lowest risk. Female sex …

Background Resources are increasingly spent on artificial intelligence (AI) solutions for
medical applications aiming to improve diagnosis, treatment, and prevention of diseases …

Introduction Arterial hypertension represents the leading modifiable risk factor for all-cause
death and early development of cardiovascular disease in women. Current clinical …

In the last three decades cutaneous melanoma has been widely investigated as a steroid
hormone-sensitive cancer. Following this hypothesis, many epidemiological studies have …

There is growing interest in interventions that delay, slow, and even reverse frailty. In this
narrative review, we explore the evidence on exercise, nutrition, medication optimisation …

The is growing awareness that the underrepresentation of women in clinical trials and in
particular in phase I studies may lead to incorrect handling of drugs. Despite the fact that …

Pharmacovigilance databases contain larger numbers of adverse drug events (ADEs) that
occurred in women compared to men. The cause of this disparity is frequently attributed to …

A widely accepted concept in perinatal medicine is that boys are more susceptible than girls
to complications of prematurity. However, whether this 'male disadvantage of …

Heart failure (HF) represents a leading cause of morbidity and mortality. However, HF trials
highlighted many differences between men and women with HF. Thus, women represent …